Research programme: cell penetrating and interfering peptides - CleveXel Pharma/PEP-Therapy
Latest Information Update: 15 Jul 2015
At a glance
- Originator CleveXel Pharma; PEP-Therapy
- Class Peptides
- Mechanism of Action Caspase 9 inhibitors; Protein phosphatase 2A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Apr 2015 Preclinical trials in Cancer in France (unspecified route)